Two Sigma Advisers’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $386K | Sell |
27,600
-7,700
| -22% | -$108K | ﹤0.01% | 1863 |
|
|
2025
Q1 | $480K | Buy |
35,300
+20,200
| +134% | +$275K | ﹤0.01% | 1796 |
|
|
2024
Q4 | $308K | Buy |
+15,100
| New | +$308K | ﹤0.01% | 1968 |
|
|
2024
Q2 | – | Sell |
-21,900
| Closed | -$449K | – | 2500 |
|
|
2024
Q1 | $449K | Buy |
+21,900
| New | +$449K | ﹤0.01% | 1915 |
|
|
2023
Q3 | – | Sell |
-26,400
| Closed | -$779K | – | 2433 |
|
|
2023
Q2 | $779K | Sell |
26,400
-91,500
| -78% | -$2.7M | ﹤0.01% | 1632 |
|
|
2023
Q1 | $2.72M | Sell |
117,900
-33,900
| -22% | -$781K | 0.01% | 1109 |
|
|
2022
Q4 | $4.22M | Sell |
151,800
-32,000
| -17% | -$890K | 0.01% | 851 |
|
|
2022
Q3 | $5.64M | Buy |
183,800
+23,300
| +15% | +$715K | 0.02% | 680 |
|
|
2022
Q2 | $4.72M | Sell |
160,500
-11,700
| -7% | -$344K | 0.01% | 802 |
|
|
2022
Q1 | $5.54M | Sell |
172,200
-97,400
| -36% | -$3.13M | 0.01% | 760 |
|
|
2021
Q4 | $12M | Sell |
269,600
-151,500
| -36% | -$6.76M | 0.03% | 447 |
|
|
2021
Q3 | $21.2M | Sell |
421,100
-43,000
| -9% | -$2.17M | 0.06% | 303 |
|
|
2021
Q2 | $36.4M | Buy |
464,100
+12,800
| +3% | +$1M | 0.1% | 219 |
|
|
2021
Q1 | $25.8M | Buy |
451,300
+190,200
| +73% | +$10.9M | 0.07% | 295 |
|
|
2020
Q4 | $21.9M | Buy |
261,100
+200,700
| +332% | +$16.8M | 0.06% | 329 |
|
|
2020
Q3 | $2.16M | Buy |
60,400
+48,200
| +395% | +$1.73M | 0.01% | 1127 |
|
|
2020
Q2 | $295K | Buy |
+12,200
| New | +$295K | ﹤0.01% | 2123 |
|